All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Balancing Act: Calculating Adjuvant Treatment Risks in Older Women With Breast Cancer

March 6th 2015

Hyman B. Muss, MD, provides expert insight on adjuvant treatment for older patients with breast cancer.

FDA Approves Zarxio as First US Biosimilar

March 6th 2015

The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.

BMS, Bavarian Nordic Forge Immunotherapy Collaboration

March 5th 2015

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

AbbVie Gains Ibrutinib Through Pharmacyclics Acquisition

March 5th 2015

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

Carey Offers Views on Evolving Chemotherapy Options-and Beyond-in TNBC

March 5th 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

NCI Director Harold Varmus Resigns

March 4th 2015

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

FDA Approves Nivolumab for Lung Cancer

March 4th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Antonarakis Discusses AR-V7 and Response to Taxanes in mCRPC

March 4th 2015

Emmanuel S. Antonarakis, MBBCh, discusses research examining AR-V7 as a biomarker for chemotherapy efficacy in advanced prostate cancer.

IU Simon Cancer Center Teams with OncLive in Strategic Alliance Partnership

March 3rd 2015

OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

Carfilzomib Doubles PFS Over Bortezomib in Phase III Multiple Myeloma Trial

March 2nd 2015

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma

March 2nd 2015

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

GSK, Novartis Product Exchange Completed

March 2nd 2015

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

Nivolumab Receives Priority Review for NSCLC

February 27th 2015

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous nonâ€“small cell lung cancer.

PD-1 Agents Vie for Frontline Spot in Melanoma Immunotherapy

February 27th 2015

New checkpoint blockade agents that target the PD-1 pathway are moving forward quickly in the melanoma treatment paradigm and likely will become a frontline immunotherapy choice for patients with advanced or metastatic disease, according to Jason J. Luke, MD, FACP, a leading researcher in the field.

Five-Year Analysis Shows Ipilimumab More Than Doubles OS in Advanced Melanoma

February 27th 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

Eribulin Extends Survival in Phase III Sarcoma Study

February 25th 2015

Treatment with eribulin mesylate significantly extended overall survival compared with dacarbazine in patients with advanced soft tissue sarcoma.

New Approvals Transform CLL Treatment, More Advances on the Horizon

February 25th 2015

For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.

OncLive Welcomes Medical University of South Carolina's Hollings Cancer Center to Strategic Alliance Partnership Program

February 25th 2015

OncLive today welcomes the Medical University of South Carolina's Hollings Cancer Center as a partner in promoting the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.

PD-1 Inhibition Requires Further Refinement in Melanoma

February 25th 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.